Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | APP | P05067 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189802 | 0.84 | SMN1; SMN2 (0.51) | RAB9AMAPTKMT2ANPC1KDM4E | |
| SCHEMBL799569 | 0.84 | SMN1; SMN2 (0.51) | RAB9AMAPTKMT2ANPC1KDM4E | |
| SCHEMBL334252 | 0.81 | NPC1 (0.61) | RAB9AMAPTKMT2ANPC1APP | |
| SCHEMBL9305118 | 0.79 | RAB9A (0.65) | RAB9AMAPTKMT2ANPC1KDM4E | |
| SCHEMBL30542465 | 0.79 | SMN1; SMN2 (0.66) | RAB9AMAPTKMT2ANPC1APP | |
| SCHEMBL84327 | 0.79 | SMN1; SMN2 (0.66) | RAB9AMAPTKMT2ANPC1APP | |
| SCHEMBL13444809 | 0.79 | MAPT (0.69) | RAB9AMAPTKMT2ANPC1APP | |
| SCHEMBL12355589 | 0.79 | MAPT (0.72) | RAB9AMAPTKMT2ANPC1APP | |
| SCHEMBL3001266 | 0.78 | KMT2A (0.54) | RAB9AMAPTKMT2ANPC1APP | |
| SCHEMBL1638573 | 0.78 | RAB9A (0.63) | RAB9AMAPTKMT2ANPC1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045993-A | Polishing solution for processing ultra-smooth low-damage bearing steel surface and application thereof | 西南交通大学 | 2021-06-29 | — | — | CN | claimed |
| CN-104419326-A | Slurry composition for chemical mechanical polishing | COWON INNOTECH INC | 2015-03-18 | — | — | CN | claimed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3458447-B1 | PIPERAZINYL METHANONE NAAA INHIBITORS | UNIV CALIFORNIA (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-115109009-B | Synthesis method of 2-sulfonyl benzothiazole compound | 东华理工大学 | 2023-10-31 | — | — | CN | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-20220402914-A1 | Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2022-12-22 | — | — | US | disclosed |
| CN-115109009-A | Synthesis method of 2-sulfonyl benzothiazole compound | 东华理工大学 | 2022-09-27 | — | — | CN | disclosed |
| US-6583157-B2 | Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1296967-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | Tularik Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| CN-1068317-C | Benzothiazole quinone and its preparation and use | UNIV HUAZHONG (CN) | 2001-07-11 | — | — | CN | disclosed |
| CN-1184106-A | Benzothiazole quinone and its preparation and use | UNIV CENTRAL CHINA NORMAL (CN) | 1998-06-10 | — | — | CN | disclosed |
| US-4880933-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0315155-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1989-05-10 | — | — | EP | disclosed |
| EP-0123087-B1 | PROCESS FOR THE PREPARATION OF HETEROCYCLIC PHENYL ETHER | CASSELLA Aktiengesellschaft (DE) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | RAB9A 2323/4885MAPT 4521/4885KMT2A 4789/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | RAB9A 2680/4885MAPT 785/4885KMT2A 1722/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | RAB9A 2680/4885MAPT 785/4885KMT2A 1722/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | RAB9A 1423/4885MAPT 3145/4885KMT2A 2448/4885 |
| US-20220402914-A1 | Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents | HNMT, TPH1, TPH2 | RAB9A 2672/4885MAPT 139/4885KMT2A 161/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | RAB9A 2680/4885MAPT 785/4885KMT2A 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.